Skip to content
Multi-Pronged Approach
Sisunatovir
- Orally administered RSV Fusion inhibitor
- High potency against RSV A and RSV B strains
- Antiviral levels achieved in plasma
- Lack of clinical resistance
- Favorable Toxicity and Tolerability Profile
- Highly potent activity against virus and symptoms in RSV challenge model
- View publication of RSV Challenge Study Data
- Partnered with LianBio (www.lianbio.com) for development and commercialization in mainland China, Hong Kong, Macau, and Singapore
N-Protein Inhibitors
- Potential for monotherapy or combination therapy
- Complementary mode of action to sisunatovir – targets different stage of viral life cycle
- Demonstrated additive combination effect in vitro